Works matching IS 20445385 AND DT 2025 AND VI 15 AND IP 1

Results: 88
    1
    2

    Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.

    Published in:
    2025
    By:
    • Jimenez-Vicente, Carlos;
    • Cardus, Aina;
    • Castaño-Diez, Sandra;
    • Ramil, Guillermo;
    • Garcia-Avila, Sara;
    • Gomez-Perez, Lucia;
    • Esteban, Daniel;
    • Arribas, Iago;
    • Sturla, Antonella Lucia;
    • Lopez-Guerra, Monica;
    • Martinez-Roca, Alexandra;
    • Cortes-Bullich, Albert;
    • Perez-Valencia, Amanda Isabel;
    • Zugasti, Ines;
    • Monge, Ines;
    • Carcelero, Esther;
    • Vall-Llovera, Ferran;
    • Vives, Susana;
    • Sierra, Jorge;
    • Nomdedeu, Josep
    Publication type:
    Letter
    3
    4

    Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01297-7
    By:
    • Pasvolsky, Oren;
    • Dima, Danai;
    • Feng, Lei;
    • Dong, Wenli;
    • Richards, Tiffany;
    • Davis, James A.;
    • Afrough, Aimaz;
    • Vazquez-Martinez, Mariola;
    • Sannareddy, Aishwarya;
    • Goel, Utkarsh;
    • Banerjee, Rahul;
    • Khouri, Jack;
    • Cervoni, Frances;
    • Gaballa, Mahmoud R.;
    • Lieberman-Cribbin, Alex;
    • Rana, Masooma Shifa;
    • Julian, Kelley;
    • Ferreri, Christopher J.;
    • Shune, Leyla;
    • DeJarnette, Shaun
    Publication type:
    Article
    5
    6
    7
    8

    CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01284-y
    By:
    • Giorgetti, Giulia;
    • Maroto-Martin, Elena;
    • Soncini, Debora;
    • Fenoglio, Daniela;
    • Becherini, Pamela;
    • Benzi, Andrea;
    • Ravera, Silvia;
    • Traverso, Isabella;
    • Ladisa, Francesco;
    • Lai, Francesco;
    • Rivoli, Giulia;
    • Truffelli, Dario;
    • Nahimana, Aimable;
    • Cagnetta, Antonia;
    • Guolo, Fabio;
    • Uras, Chiara R. M.;
    • Schavgoulidze, Anaïs;
    • Fong Ng, Jessica;
    • Nencioni, Alessio;
    • Bruzzone, Santina
    Publication type:
    Article
    9
    10

    Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01291-z
    By:
    • de Groen, Ruben A. L.;
    • de Groot, Fleur A.;
    • Böhringer, Stefan;
    • Kret, Esther J.;
    • de Haan, Lorraine M.;
    • Noordenbos, Troy;
    • Blommers, Susan;
    • Jansen, Romée E. W.;
    • van Wezel, Tom;
    • van Eijk, Ronald;
    • Raghoo, Richard;
    • Ruano, Dina;
    • Boome, Liane te;
    • Terpstra, Valeska;
    • Levenga, Henriette;
    • Ahsmann, Els;
    • Posthuma, Eduardus F. M.;
    • Focke-Snieders, Isabelle;
    • Hardi, Lizan;
    • den Hartog, Wietske C. E.
    Publication type:
    Article
    11
    12
    13
    14

    Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01279-9
    By:
    • Narula, Gaurav;
    • Keerthivasagam, Swaminathan;
    • Jain, Hasmukh;
    • Punatar, Sachin;
    • Chichra, Akanksha;
    • Dhamne, Chetan;
    • Tembhare, Prashant;
    • Subramanian, Papagudi Ganesan;
    • Patkar, Nikhil;
    • Poojary, Minal;
    • Gokarn, Anant;
    • Mirgh, Sumeet;
    • Jindal, Nishant;
    • Nisar, Albeena;
    • Pandit, Deepali;
    • Pandit, Khushali;
    • Dwivedi, Alka;
    • Karulkar, Atharva;
    • Jaiswal, Ankesh Kumar;
    • Khan, Aalia
    Publication type:
    Article
    15

    Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01272-2
    By:
    • Cirstea, Diana;
    • Shome, Rajib;
    • Samur, Mehmet;
    • Talluri, Srikanth;
    • Connolly, Joseph J.;
    • Wright, Alexandra Jean;
    • Duvallet, Emilie;
    • Joyce, Amanda N. R.;
    • Lively, Kathleen;
    • Basinsky, Gina;
    • Yee, Andrew J.;
    • Chase, Cristiana Costa;
    • Malek, Ehsan;
    • Niesvizky, Ruben;
    • Richardson, Paul G.;
    • Raje, Noopur S.
    Publication type:
    Article
    16

    Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01266-0
    By:
    • Akiyama, Hiroki;
    • Nishida, Yuki;
    • Chang, Kyung Hee;
    • Bedoy, Andrea D.;
    • Muftuoglu, Muharrem;
    • Ma, Wencai;
    • Basyal, Mahesh;
    • Hirschi, Zoe;
    • Honma, Daisuke;
    • Tsutsumi, Shinji;
    • Wang, Jing;
    • Zhang, Weiguo;
    • Huang, Xuelin;
    • Rampal, Raajit K.;
    • Oluwole, Olalekan O.;
    • Bixby, Dale Lee;
    • Daver, Naval G.;
    • Andreeff, Michael
    Publication type:
    Article
    17

    Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01241-9
    By:
    • Sarkozy, Clémentine;
    • Chartier, Loïc;
    • Ribrag, Vincent;
    • Gressin, Remy;
    • Geisler, Christian H.;
    • Kluin-Nelemans, Hanneke C.;
    • Thieblemont, Catherine;
    • Morschhauser, Franck;
    • Lemonnier, François;
    • Safar, Violaine;
    • Tessoulin, Benoît;
    • Oberic, Lucie;
    • Damaj, Ghandi;
    • Ghesquières, Hervé;
    • Bouabdallah, Krimo;
    • Casasnovas, René Olivier;
    • Houot, Roch;
    • Klapper, Wolfram;
    • Burroni, Barbara;
    • Pott, Christiane
    Publication type:
    Article
    18

    Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01282-0
    By:
    • Mohan, Meera;
    • Szabo, Aniko;
    • Cheruvalath, Heloise;
    • Clennon, Anna;
    • Bhatlapenumarthi, Vineel;
    • Patwari, Anannya;
    • Balev, Metodi;
    • Bhutani, Divaya;
    • Shrestha, Asis;
    • Thanendrarajan, Sharmilan;
    • Dhakal, Binod;
    • Zangari, Maurizio;
    • Trikannad, Anup;
    • Vellanki, Sruthi;
    • Al-Hadidi, Samer;
    • Lentzsch, Suzanne;
    • van Rhee, Frits;
    • Bag, Aishee;
    • D'Souza, Anita;
    • Shah, Nishi
    Publication type:
    Article
    19
    20
    21
    22

    Risk of lymphoid malignancy associated with cancer predisposition genes.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01283-z
    By:
    • Boddicker, Nicholas J.;
    • Mwangi, Raphael;
    • Robinson, Dennis P.;
    • Allmer, Cristine;
    • Rosenthal, Allison C.;
    • Habermann, Thomas M.;
    • Feldman, Andrew L.;
    • Rimsza, Lisa M.;
    • King, Rebecca L.;
    • Larson, Melissa C.;
    • Negaard, Bri J.;
    • Norman, Aaron D.;
    • Rajkumar, Nikhil;
    • Ansell, Stephen M.;
    • Dispenzieri, Angela;
    • Murray, David L.;
    • Rajkumar, Vincent;
    • Kumar, Shaji;
    • Abeykoon, Jithma P.;
    • Nowakowski, Grzegorz S.
    Publication type:
    Article
    23

    Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01275-z
    By:
    • Pérez-Lamas, Lucía;
    • Segura Diaz, Adrián;
    • García Delgado, Regina;
    • Álvarez-Larrán, Alberto;
    • Senin, María Alicia;
    • Mora, Elvira;
    • Fox, María Laura;
    • Pastor Galan, Irene;
    • Azaceta, Gemma;
    • Garrido Paniagua, Sara;
    • Pérez Lopez, Raúl;
    • Trejos Carvajal, Diana Margarita;
    • Angona, Anna;
    • Albo López, Carmen;
    • Lorente Alegre, Pablo;
    • Vara, Miriam;
    • Vera Goñi, Juan Antonio;
    • De Miguel Llorente, Dunia;
    • Fernández Rodríguez, Ángeles;
    • Marín Sanchez, Alberto
    Publication type:
    Article
    24

    Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01269-x
    By:
    • Willekens, Christophe;
    • Bazinet, Alexandre;
    • Chraibi, Samy;
    • Bataller, Alex;
    • Decroocq, Justine;
    • Arani, Naszrin;
    • Carpentier, Benjamin;
    • Rausch, Caitlin;
    • Lebon, Delphine;
    • Maiti, Abhishek;
    • Gauthier, Nicolas;
    • Short, Nicholas;
    • Bonnet, Sarah;
    • Sasaki, Koji;
    • Khalife-Hachem, Sabine;
    • Swaminathan, Mahesh;
    • Micol, Jean-Baptiste;
    • Pasquier, Florence;
    • Marzac, Christophe;
    • Roos-Weil, Damien
    Publication type:
    Article
    25
    26

    Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01254-4
    By:
    • Chunara, Farheen;
    • Lugo, Chris;
    • Osinski, Kristen;
    • Shah, Mansi R.;
    • Shah, Nishi;
    • Kent, Jessica;
    • Mohyuddin, Ghulam Rehman;
    • Radhakrishnan, Sabarinath Venniyil;
    • Kaur, Gurbakhash;
    • Chakraborty, Rajshekhar;
    • Banerjee, Rahul;
    • Rasche, Leo;
    • Schinke, Carolina;
    • D'Souza, Anita;
    • Szabo, Aniko;
    • Mohan, Meera
    Publication type:
    Article
    27
    28

    Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01264-2
    By:
    • Bolarinwa, Abiola;
    • Nagaraj, Madhu;
    • Zanwar, Saurabh;
    • Abdallah, Nadine;
    • Bergsagel, P. Leif;
    • Binder, Moritz;
    • Buadi, Francis;
    • Chhabra, Saurabh;
    • Cook, Joselle;
    • Dingli, David;
    • Dispenzieri, Angela;
    • Gertz, Morie A.;
    • Gonsalves, Wilson;
    • Hayman, Suzanne;
    • Kapoor, Prashant;
    • Kourelis, Taxiarchis;
    • Leung, Nelson;
    • Lin, Yi;
    • Muchtar, Eli;
    • Parrondo, Ricardo
    Publication type:
    Article
    29

    Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01261-5
    By:
    • Palfi, Stefanie;
    • Peres, Lauren C.;
    • Koelmeyer, Himara;
    • Alsina, Melissa;
    • Baz, Rachid C.;
    • Blue, Brandon J.;
    • Corallo, Salvatore;
    • De Avila, Gabriel;
    • Freeman, Ciara;
    • Gonzalez, Rebecca;
    • Grajales-Cruz, Ariel;
    • Harvey, Kristy;
    • Liu, Hien D.;
    • Nishihori, Taiga;
    • Oliveira, Guilherme H.;
    • Oswald, Laura B.;
    • Castaneda Puglianini, Omar;
    • Selvakumar, Sruthi;
    • Sharma, Alexis Behne;
    • Wang, Elicia
    Publication type:
    Article
    30
    31
    32

    Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01271-3
    By:
    • Sawalha, Y.;
    • Sarosiek, S.;
    • Welkie, R. L.;
    • Seif, S.;
    • Thapa, S.;
    • Zanwar, S.;
    • Cahill, K.;
    • Treitman, R.;
    • Shah, H.;
    • Arora, S.;
    • Pongas, G.;
    • Winter, A.;
    • Major, A.;
    • Riedell, P. A.;
    • Palomba, M. L.;
    • Kapoor, P.;
    • Grajales-Cruz, A.;
    • Shain, K. H.;
    • Thomas, S. K.;
    • Castillo, J. J.
    Publication type:
    Article
    33

    CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01273-1
    By:
    • Luna, Alejandro;
    • Devlin, Sean M.;
    • Rejeski, Kai;
    • Flynn, Jessica R.;
    • Corona, Magdalena;
    • Luttwak, Efrat;
    • Rivas-Delgado, Alfredo;
    • Landego, Ivan;
    • Cassanello, Giulio;
    • Gomez-Llobell, Marina;
    • Raj, Sandeep S.;
    • Dahi, Parastoo B.;
    • Lin, Richard J.;
    • Parascondola, Allison;
    • Palomba, M.Lia;
    • Shah, Gunjan L.;
    • Scordo, Michael;
    • Alarcon Tomas, Ana;
    • Leithner, Doris;
    • Bedmutha, Akshay
    Publication type:
    Article
    34
    35
    36

    Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01260-6
    By:
    • Lussana, Federico;
    • Magnani, Chiara F.;
    • Galimberti, Stefania;
    • Gritti, Giuseppe;
    • Gaipa, Giuseppe;
    • Belotti, Daniela;
    • Cabiati, Benedetta;
    • Napolitano, Sara;
    • Ferrari, Silvia;
    • Moretti, Alex;
    • Buracchi, Chiara;
    • Borleri, Gian Maria;
    • Rambaldi, Benedetta;
    • Rizzuto, Giuliana;
    • Grassi, Anna;
    • Paganessi, Muriel;
    • Meli, Cristian;
    • Tettamanti, Sarah;
    • Risca, Giulia;
    • Pais, Giulia
    Publication type:
    Article
    37

    VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01265-1
    By:
    • Swaminathan, Mahesh;
    • DiNardo, Courtney D.;
    • Maiti, Abhishek;
    • Pemmaraju, Naveen;
    • Ohanian, Maro;
    • Daver, Navel G.;
    • Garcia-Manero, Guillermo;
    • Issa, Ghayas C.;
    • Borthakur, Gautam;
    • Ravandi, Farhad;
    • Montalban-Bravo, Guillermo;
    • Kadia, Tapan M.;
    • Alvarado, Yesid;
    • Jabbour, Elias J.;
    • Short, Nicholas J.;
    • Wierda, William G.;
    • Jain, Nitin;
    • Kornblau, Steven M.;
    • Masarova, Lucia;
    • Pierce, Sherry A.
    Publication type:
    Article
    38

    Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01245-5
    By:
    • Bataller, Alex;
    • Sasaki, Koji;
    • Urrutia, Samuel;
    • Montalban-Bravo, Guillermo;
    • Bazinet, Alexandre;
    • Chien, Kelly;
    • Hammond, Danielle;
    • Bouligny, Ian M.;
    • Swaminathan, Mahesh;
    • Issa, Ghayas;
    • Short, Nicholas;
    • Daver, Naval;
    • DiNardo, Courtney D.;
    • Kadia, Tapan;
    • Jabbour, Elias;
    • Ravandi, Farhad;
    • Roboz, Gail J.;
    • Savona, Michael;
    • Griffiths, Elizabeth A.;
    • McCloskey, James
    Publication type:
    Article
    39

    Symptom burden in myeloproliferative neoplasms: clinical correlates, dynamics, and survival impact—a study of 784 patients from the Quebec MPN research group.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01234-8
    By:
    • Poullet, Alisa;
    • Busque, Lambert;
    • Sirhan, Shireen;
    • Delage, Robert;
    • Cournoyer, Ghislain;
    • Chamakhi, Ines;
    • Talbot, Danielle;
    • Mollica, Luigina;
    • Marceau, Daniele;
    • Ethier, Vincent;
    • Desjardins, Pierre;
    • Olney, Harold J.;
    • Harnois, Michaël;
    • Szuber, Natasha
    Publication type:
    Article
    40

    Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01257-1
    By:
    • Voorhees, Timothy J.;
    • McLaughlin, Eric M.;
    • Torka, Pallawi;
    • Florindez, Jorge;
    • Kim, Na Hyun;
    • Moyo, Tamara K.;
    • Reves, Heather;
    • Sumransub, Nuttavut;
    • Deshpande, Saarang;
    • Rose, Ashley;
    • Duarte, Cassandra;
    • Faisal, Muhammad Salman;
    • Hamid, Showkat;
    • Subbiah, Suki;
    • Ayyappan, Sabarish;
    • Shea, Lauren;
    • Cortese, Matt;
    • Patel, Krish;
    • Major, Ajay;
    • Saeed, Hayder
    Publication type:
    Article
    41

    Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01245-5
    By:
    • Bataller, Alex;
    • Sasaki, Koji;
    • Urrutia, Samuel;
    • Montalban-Bravo, Guillermo;
    • Bazinet, Alexandre;
    • Chien, Kelly;
    • Hammond, Danielle;
    • Bouligny, Ian M.;
    • Swaminathan, Mahesh;
    • Issa, Ghayas;
    • Short, Nicholas;
    • Daver, Naval;
    • DiNardo, Courtney D.;
    • Kadia, Tapan;
    • Jabbour, Elias;
    • Ravandi, Farhad;
    • Roboz, Gail J.;
    • Savona, Michael;
    • Griffiths, Elizabeth A.;
    • McCloskey, James
    Publication type:
    Article
    42
    43
    44

    Deep immune cell profiling in blood and bone marrow of early stage monoclonal gammopathy: an iStopMM and ECRIN-M3 collaborative study.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01255-3
    By:
    • Pérez-Escurza, Oihane;
    • Flores-Montero, Juan;
    • Óskarsson, Jón Þórir;
    • Sanoja-Flores, Luzalba;
    • Pozo, Julio;
    • Lécrevisse, Quentin;
    • Martín, Silvia;
    • Reed, Elín Ruth;
    • Hákonardóttir, Guðlaug Katrín;
    • Harding, Stephen;
    • Þorsteinsdóttir, Sigrún;
    • Rögnvaldsson, Sæmundur;
    • Love, Thorvardur Jon;
    • Durie, Brian;
    • Kristinsson, Sigurdur Yngvi;
    • Orfao, Alberto
    Publication type:
    Article
    45
    46

    Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01263-3
    By:
    • Pullarkat, Vinod;
    • Pratz, Keith W.;
    • Döhner, Hartmut;
    • Recher, Christian;
    • Thirman, Michael J.;
    • DiNardo, Courtney D.;
    • Fenaux, Pierre;
    • Schuh, Andre C.;
    • Wei, Andrew H.;
    • Pigneux, Arnaud;
    • Jang, Jun-Ho;
    • Juliusson, Gunnar;
    • Miyazaki, Yasushi;
    • Selleslag, Dominik;
    • Arellano, Martha L.;
    • Liu, Chenglong;
    • Ridgeway, Jean A.;
    • Potluri, Jalaja;
    • Schuler, Jovita;
    • Konopleva, Marina
    Publication type:
    Article
    47
    48

    Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC).

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01223-x
    By:
    • Jiménez-Vicente, Carlos;
    • Esteve, Jordi;
    • Baile-González, Mónica;
    • Pérez-López, Estefanía;
    • Martin Calvo, Carmen;
    • Aparicio, Clara;
    • Oiartzabal Ormategi, Itziar;
    • Esquirol, Albert;
    • Peña-Muñoz, Felipe;
    • Fernández-Luis, Sara;
    • Heras Fernando, Inmaculada;
    • González-Rodríguez, Ana Pilar;
    • López-García, Alberto;
    • López-Lorenzo, Jose Luis;
    • Torrado, Tamara;
    • Sáez Marín, Adolfo Jesús;
    • Acosta Fleytas, Cynthia;
    • García, Lucía;
    • Villar, Sara;
    • Filaferro, Silvia
    Publication type:
    Article
    49

    Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01251-7
    By:
    • Fiskus, Warren;
    • Mill, Christopher P.;
    • Piel, Jessica;
    • Collins, Mike;
    • Hentemann, Murphy;
    • Cuglievan, Branko;
    • Birdwell, Christine E.;
    • Das, Kaberi;
    • Hou, Hanxi;
    • Davis, John A.;
    • Jain, Antrix;
    • Malovannaya, Anna;
    • Kadia, Tapan M.;
    • Daver, Naval;
    • Sasaki, Koji;
    • Takahashi, Koichi;
    • Hammond, Danielle;
    • Reville, Patrick K.;
    • Flores, Lauren B.;
    • Loghavi, Sanam
    Publication type:
    Article
    50

    Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01248-2
    By:
    • Soureas, Konstantinos;
    • Malandrakis, Panagiotis;
    • Papadimitriou, Maria-Alexandra;
    • Minopoulos, Christos;
    • Ntanasis-Stathopoulos, Ioannis;
    • Liacos, Christine-Ivy;
    • Gavriatopoulou, Maria;
    • Kastritis, Efstathios;
    • Dimopoulos, Meletios-Athanasios;
    • Scorilas, Andreas;
    • Avgeris, Margaritis;
    • Terpos, Evangelos
    Publication type:
    Article